Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

The senior author is Roger Innes, Distinguished Professor of Biology. "What excites us most about this discovery is that it indicates plants may control their microbiomes, in part, by regulating gene ...

[28] RNA interference (RNAi) is a naturally occurring biological pathway in which small, double-stranded RNA molecules suppress gene expression in an exquisitely sequence-specific manner Exogenous ...

This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal ...

"What excites us most about this discovery is that it indicates plants may control their microbiomes, in part, by regulating gene expression in microbes using cross-kingdom RNA interference ...

With its International Headquarters in Zug, Switzerland, Alnylam has become a key part of the Swiss biotech environment.

The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.

Benitec has a market cap of $250mn, $67.8mn in cash, and a cash runway of over 10 quarters, but faces risks due to its small ...

Vietnam RNAi Therapeutics Market Key Takeaways: The Vietnam RNAi Therapeutics market is undergoing robust growth, fueled by factors such as advancements in RNA interference (RNAi) technology, a ...

What excites us most about this discovery is that it indicates plants may control their microbiomes, in part, by regulating gene expression in microbes using cross-kingdom RNA interference ...